Ratification Date: 01/04/2025
Next Review Date: 01/04/2027
Tirofiban – Prevention of MI in unstable angina
Drug Name (Brand) | Tirofiban (Aggrastat®) | |||
Indication | Prevention of MI in unstable angina | |||
Traffic Light Classification | Red | |||
NICE TA (plus link) | TA47 – Sep 02
|
|||
Further Information:
NICE recommendations, summary of meeting discussions, links to additional supporting docs etc.
NICE September 2002 (Glycoprotein IIb/IIIa inhibitors for acute coronary syndromes No. 47): Includes abciximab, eptifibatide, and tirofiban – these drugs should be considered in the management of unstable angina or non-ST-segment-elevation MI. For patients at high risk of MI or death when early Percutaneous Coronary Intervention (PCI) is desirable but does not occur immediately; either eptifibatide or tirofiban is recommended in addition to other appropriate drug treatment. A Glycoprotein IIb/IIIa Inhibitor is recommended as an adjunct to PCI: * when early PCI is indicated but is delayed * in patinets with diabetes * if the procedure is complex NB only abciximab is licensed as an adjunct to PCI. unstable angina or non-Q-wave myocardial infarction the intravenous use of the glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors (consistent with current UK licensing), in addition to aspirin and low (adjusted) dose unfractionated heparin, is recommended.
|
||||
Date of TAG recommendation / ratification | Review Date | 1/4/2027 |